ZEB1-AS1: A Potential Drug Target and Biomarker (G220930)

Target Name: ZEB1-AS1

NCBI ID: G220930

ZEB1-AS1

Other Name(s): ZEB1 antisense RNA 1 | ZEB1-AS1 variant 1

ZEB1-AS1: A Potential Drug Target and Biomarker

ZEB1-AS1, a synthetic RNA interference (RNAi) targeting specific genes, has been identified as a potential drug target and biomarker for various diseases. ZEB1-AS1 is derived from the ZEB1 gene, which encodes for the protein ZEB1, a key regulator of microRNA (miRNA) expression in various organisms. ZEB1-AS1 has been shown to interact with several protein targets, including known drug targets, such as the nuclear factor of activating transcription factor (NFAT) and the RNA-protein binding protein (RBP) complex. These interactions may suggest a role for ZEB1-AS1 in modulating gene expression and potentially targeting diseases associated with aberrant miRNA regulation.

In recent years, the identification of gene-based drug targets has become a major focus in the pharmaceutical industry. miRNA pathways have emerged as a promising target for drug development due to their involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The miRNA system plays a crucial role in regulating gene expression by targeting specific mRNAs for degradation or translation, thereby controlling cellular processes such as cell growth, apoptosis, and inflammation.

One of the key challenges in the development of drug targets for miRNA pathways is the complexity of miRNA regulation. miRNA expression can be highly context-dependent, meaning that the same miRNA can have different effects depending on the cell type, target, and context. This complexity can make it difficult to predict the efficacy of a miRNA-based drug. However, recent studies have identified potential biomarkers and drug targets for miRNA pathways, including ZEB1-AS1.

ZEB1-AS1, a synthetic RNA interference targeting specific genes, has been shown to interact with several protein targets, including known drug targets, such as the nuclear factor of activating transcription factor (NFAT) and the RNA-protein binding protein (RBP) complex. These interactions may suggest a role for ZEB1-AS1 in modulating gene expression and potentially targeting diseases associated with aberrant miRNA regulation.

The NFAT pathway is a well-established target for miRNA regulation in various organisms. NFAT is a transcription factor that plays a crucial role in regulating gene expression by binding to specific DNA sequences. ZEB1-AS1 has been shown to interact with the NFAT transcription factor, leading to the inhibition of miRNA-mediated gene repression. This interaction between ZEB1-AS1 and NFAT suggests a potential role for ZEB1-AS1 in targetingNFAT-regulated genes, potentially leading to therapeutic interventions for diseases associated withNFAT dysfunction.

The RBP complex is another well-established target for miRNA regulation. RBP is a protein that can interact with specific miRNAs to target them for degradation. ZEB1-AS1 has been shown to interact with miRNAs, includinglet-2 (Let-2), a miRNA that plays a role in regulating cell proliferation and has been implicated in various diseases, such as cancer. This interaction between ZEB1-AS1 and Let-2 suggests a potential role for ZEB1-AS1 in targeting miRNAs associated with disease, potentially leading to therapeutic interventions for diseases associated with aberrant miRNA regulation.

In conclusion, ZEB1-AS1, a synthetic RNA interference targeting specific genes, has been identified as a potential drug target and biomarker for various diseases. The interaction between ZEB1-AS1 and NFAT and RBP suggests a potential role for ZEB1-AS1 in targetingNFAT-regulated genes and miRNAs associated with disease. Further studies are needed to determine the efficacy and safety of ZEB1-AS1 as a drug

Protein Name: ZEB1 Antisense RNA 1

The "ZEB1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZEB1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets